Specific autoantibodies associated with blood vessel damage in the brain

The presence of specific autoantibodies of the immune system is associated with blood vessel damage in the brain. These findings were made by Marion Bimmler, a graduate engineer of medical laboratory diagnostics at the Max Delbr-ck Center for Molecular Medicine Berlin-Buch and Dr. Peter Karczewski of the biotech company E.R.D.E.-AAK-Diagnostik GmbH in studies on a rat model. The researchers' results suggest that autoimmune mechanisms play a significant role in the pathogenesis and progression of Alzheimer's and vascular dementia (PloS ONE, doi:10.1371/journal.pone.0041602).

Antibodies are the defense molecules of the body's immune system against foreign invaders. If the antibodies cease to distinguish between "foreign" and "self", they attack the cells of the own body, and are thus referred to as autoantibodies. These can trigger autoimmune diseases. Using MR angiography and other methods, Marion Bimmler and her colleagues have now shown that the autoantibodies bind to specific surface proteins (alpha1 andrenergic receptors) of vascular cells and thereby damage the blood vessels of the brain. The reason: The autoantibodies generate a continual stimulation of the receptor and at the same time trigger an increase in intracellular calcium ion levels. As a result, the blood vessel walls thicken, and blood flow to the brain is disturbed.

First Encouraging Results after Removal of Autoantibodies by Immunoadsorption

In earlier studies, Marion Bimmler and her research team examined blood samples of patients with Alzheimer's or vascular dementia and showed that half of them had comparable autoantibodies. A first clinical trial together with Charit- - Universit-tsmedizin Berlin is currently ongoing with a collective of patients with Alzheimer's or vascular dementia. The patients were divided into two groups - a small group whose autoantibodies were removed from the blood via immunoadsorption and a control group that did not receive this treatment. Until now, over an observation period of 6 and subsequently 12 months, the patient group who had undergone immunoadsorption improved in their memory performance and in their ability to cope with their everyday lives. In contrast, the condition of the patients who did not receive immunoadsorption treatment and continued to have autoantibodies in their blood deteriorated dramatically. Now the researchers are planning further clinical trials with larger numbers of patients.